PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia

s | 47 scores. A linear regression analysis revealed that being male and married had significant positive associations with sexual arousal, sexual satisfaction, and/or sexual desire, while the presence of TD and a longer duration of illness were associated with poor sexual arousal and/or sexual desire. Additionally, sexual function was significantly associated with SWN-K and DAI scores in multivariate analysis. Conclusions: The acknowledgement and management of sexual dysfunction in patients with schizophrenia by clinicians may be important for improvement of their quality of life and adherence to medication. PM403 Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia Jung Suk Lee1, Byung Ook Lee2, Hui Woo Yoon2 1Jesaeng Hospital, Republic of Korea, 2National Health Insurance Service Ilsan Hospital, Republic of Korea Abstract Objective: Hyperprolactinemia is an important but often overlookedObjective: Hyperprolactinemia is an important but often overlooked side effect of antipsychotics. Addition of and switching to aripiprazole normalized antipsychotics-induced hyperprolactinemia in several studies. However, there was no study that directly compared the effectiveness and safety of both strategies. Method: A total 52 patients with antipsychotics-induced hyperprolactinemia were recruited. Aripiprazole was added to patients with mild hyperprolactinemia (serum prolactin level lower than 50ng/ml). Patients with severe hyperprolactinemia (serum prolactin level higher than 50ng/ml) were randomized to aripiprazole addition group (adding aripiprazole to previous antipsychotics) or switching group (switching previous antipsychotics to aripiprazole). Serum prolactin levels, menstrual disturbances, sexual dysfunctions, psychopathologies, quality of life were measured at weeks 0, 1, 2, 4, 6 and 8. Results: Both addition and switching strategies significantly reduced serum prolactin levels (F(1, 199)=76.09, p<0.001) and menstrual disturbances (χ2=63.86, df=5, p<0.001) over time and they improved sexual dysfunctions (χ2=12.03, df=5, p=0.03) in all groups. In patients with severe hyperprolactinemia, number of patients with hyperprolactinemia (χ2=6.30, df=1, p=0.01) and menstrual disturbance (χ2=4.31, df=1, p=0.04) in switching group was significantly lower than that in addition group at week 8. Conclusion: Both addition and switching strategies were effective in resolving antipsychotics-induced hyperprolactinemia and hyperprolactinemia related adverse events including menstrual disturbances and sexual dysfunctions. These findings suggest that switching to aripiprazole may be more effective in normalizing hyperprolactinemia and improving hyperprolactinemia related adverse events in patients with schizophrenia. PM405 Sodium Benzoate Add-on Treatment for Refractory Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial Chieh-Hsin Lin, MD, PhD, Yue-Cune Chang, PhD, Hsien-Yuan Lane,